首页> 外国专利> TREATMENT OF BILIARY CIRRHOSIS BASED ON OXYNTOMODULIN ANALOGUE GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE

TREATMENT OF BILIARY CIRRHOSIS BASED ON OXYNTOMODULIN ANALOGUE GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE

机译:基于氧单向素类似物GLP-1R / GCGR双靶激动剂肽的胆汁肝硬化治疗

摘要

The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), characterized by high enzymolysis stability, high biological activity and no adverse reaction. The polypeptide compounds are able to significantly improve a degree of BDL-induced cholestasis hepatic fibrosis in rats, and have significant therapeutic effects on diseases such as biliary cirrhosis. The dual target agonist polypeptides are applicable to the prevention or treatment of biliary cirrhosis and related hepatic fibrosis diseases.
机译:本发明涉及具有双靶诱导胰高血糖素(GLP-1R)和胰高血糖素受体(GCGR)的胰高血糖素对胰高血糖素(GCGR)的多肽化合物的用途,其特征在于高酶解稳定性,高生物活性和不良反应。多肽化合物能够显着提高大鼠的BDL诱导的胆囊炎肝纤维化程度,对胆汁肝硬化等疾病具有显着的治疗作用。双靶激动剂多肽适用于预防或治疗胆道肝硬化和相关肝纤维化疾病。

著录项

  • 公开/公告号US2021187074A1

    专利类型

  • 公开/公告日2021-06-24

    原文格式PDF

  • 申请/专利权人 SHENZHEN TURIER BIOTECH CO. LTD.;

    申请/专利号US201816760894

  • 发明设计人 LEI WANG;JIANMEI OUYANG;

    申请日2018-10-19

  • 分类号A61K38/26;A61P1/16;

  • 国家 US

  • 入库时间 2022-08-24 19:32:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号